NDF Research yesterday released its initiation report on Anatara Lifesciences Ltd (ASX:ANR). The report provided a valuation at $2.22 per share base case and $5.94 per share optimistic case using a DCF approach, with a target price of $4.00 per share sitting midpoint of their valuation range.
Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see http://www.anataralifesciences.com for further background.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its updated investor presentation.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's AGM Presentation held on 15 November 2016.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's latest Chairman's Address to Shareholders at 2016 AGM.
Anatara Lifesciences Ltd (ASX:ANR) directors present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the year ended 30 June 2016.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received $420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. This refund is from Anatara's 2014-15 research activities and future refunds will increase significantly. The company is in the process of finalising its 2015-16 tax claim.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.
Anatara Lifesciences Limited's (ASX:ANR) Antibiotic Alternative Edges Closer to Commercialisation as UN Declares Drug Resistance 'The Greatest and Most Urgent global risk'
Following the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), Anatara Lifesciences (ASX:ANR) confirmed its commitment to fighting AMR, starting with the food chain. Anatara, which is developing therapeutics for gastrointestinal diseases in production animals and humans announced today it had submitted an application to register Detach(TM).
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has lodged its application for approval to register Detach(TM) with the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach(TM) is a natural, non-antibiotic alternative for the control of diarrhoea in piglets.
Anatara Lifesciences (ASX:ANR) is pleased to announce the successful completion of its pivotal Target Animal Safety (TAS) Study for DetachTM, the Company's lead product for the control of diarrhoea in piglets.